Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome

Marc Sorigue, Javier Nieto, Mireia Santos-Gomez, Edurne Sarrate, Maria José Jiménez, Cristian Morales-Indiano, Laia Lopez-Viaplana, Elisa Orna, Jose Tomas Navarro, Josep Maria Ribera, Blanca Xicoy

Research output: Contribution to journalArticleResearch

Abstract

© 2018 Elsevier Ltd Myelodysplastic syndrome (MDS) and antithrombotic medication both increase the risk of bleeding. We set out to analyze the prevalence of use, indications and bleeding risk of antithrombotic therapy in patients with MDS in a retrospective, single-center study including all patients with MDS with >20 × 10 9 /L platelets. 193 patients (59% male, median age 75 years) were included; 122 did not receive antithrombotic treatment, 51 received antiplatelet agents and 20 received anticoagulants. The cumulative incidence of major bleeding was higher in both the antiplatelet group (11.8% at 4 years, 95% confidence interval [95%CI]: 4.7–22.3%) and the anticoagulation group (21.2% at 4 years, 95%CI 6–42.5%) than in the control group (2.8% at 4 years 95%CI: 0.7–7.3%). The prevalence of use of antithrombotic medication in this cohort of patients with MDS was high and bleeding risk was increased in these patients.
Original languageEnglish
Pages (from-to)24-28
JournalLeukemia Research
Volume73
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Anticoagulation
  • Antiplatelet agents
  • Atrial fibrillation
  • Bleeding
  • Myelodysplastic syndrome
  • Thrombocytopenia

Fingerprint Dive into the research topics of 'Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this